New approach to clinical evaluation of nail lesions in psoriasis

Saranyuk R.V.; Polonikov A.V.

doi:https://doi.org/10.17116/klinderma202524041453

Saranyuk R.V.

Kursk State Medical University;
Society of integrative dermatology

ORCID: 0000-0001-9676-1581

Polonikov A.V.

Kursk State Medical University

ORCID: 0000-0001-6280-247X

New approach to clinical evaluation of nail lesions in psoriasis

Authors:

Saranyuk R.V., Polonikov A.V.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2025;24(4): 453‑460

DOI: 10.17116/klinderma202524041453

Read: 434 times

Contact the author

Table of contents

To cite this article:

Saranyuk RV, Polonikov AV. New approach to clinical evaluation of nail lesions in psoriasis. Russian Journal of Clinical Dermatology and Venereology. 2025;24(4):453‑460. (In Russ.)
https://doi.org/10.17116/klinderma202524041453

Подписка 2026 Клиническая дерматология и венерология (Russian Journal of Clinical Dermatology and Venereology)

Использование инфографики авторами научных работ

BACKGROUND

Psoriatic onychodystrophy is difficult to treat being a psoriasis of complex localizations. Possibilities of clinical assessment of nail lesions in psoriasis and efficacy of the performed therapy are currently severely limited due to the laborious process of working with existing indices, which are difficult to be applied in the evaluation of psoriatic onychodystrophy over time.

OBJECTIVE

Study of the prevalence of psoriatic onychodystrophy, as well as a proposal of an own method for assessing its course severity and the treatment efficacy. We have also tried to introduce a new term, namely «psoriatic dyad» to denote the severe course of nail psoriasis.

MATERIAL AND METHODS

Between 2018 and 2021, 509 patients with the established «psoriasis» diagnosis were examined. Nail lesions in patients with psoriasis were assessed using the psoriatic onychodystrophy severity index (NAPSI).

RESULTS

Nail lesions were noted in 133 (59.3%) patients. The most common types of nail lesions were nail pitting (72/54.1%) and «oil drop» symptom together with onycholysis (57/42.8%). Based on the literature data and own research we have developed an algorithm for assessment of the severity of nail psoriasis course — scale of evaluation of therapy and severity of psoriatic onychodystrophy — NAPTSS (Nail Psoriasis Therapy and Severity Score), considering 2 signs of lesion for the nail matrix (nail pitting, Beau’s lines and onychomadesis) and 2 — for the nail bed (longitudinal hemorrhages, «oil drop» symptom and onycholysis). In case of combined lesion of the nail matrix and nail bed, we have proposed «psoriatic dyad» term.

CONCLUSION

Proposed NAPTSS scale is an attempt to create a simple and practical system for assessing nail damage in psoriasis and the efficacy of treatment. We believe that «psoriatic dyad» term is necessary for indicating severe clinical situation of combined lesion both of the nail matrix and of the nail bed.

Keywords:

psoriasis

psoriatic onychodystrophy

NAPSI

NAPTSS

onycholysis

Authors:

Saranyuk R.V.

Kursk State Medical University;
Society of integrative dermatology

ORCID: 0000-0001-9676-1581

Polonikov A.V.

Kursk State Medical University

ORCID: 0000-0001-6280-247X

Received:

02.07.2024

Accepted:

20.05.2025

Close metadata

References:

National Psoraisis Foundation. Accessed October 1, 2015 www.psoriasis.org/cure_known_statistics
Lanna C, Galluzzi C, Zangrilli A, Bavetta M, Bianchi L & Campione E. Psoriasis in difficult to treat areas: treatment role in improving health-related quality of life and perception of the disease stigma. Journal of Dermatological Treatment. 2022;33(1):531-534. https://doi.org/10.1080/09546634.2020.1770175
Jiaravuthisan MM, Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J AmAcadDermatol. 2007;57(1):1-27.
Maejima H, Taniguchi T, Watarai A, Katsuoka K. Evaluation of nail disease in psoriatic arthritis by using a modified nail psoriasis severity score index. Int JDermatol. 2010;49(8):901-906.
Langenbruch A, Radtke MA, Krensel M, Jacobi A, Reich K, Augustin M. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. Br J Dermatol. 2014;171(5):1123-1128.
Williamson L, Dalbeth N, Dockerty JL, Gee BC, Weatherall R, Wordsworth BP. Extended report: nail disease in psoriatic arthritis—clinically important, potentially treatable and often overlooked. Rheumatology (Oxford). 2004;43(6):790-794.
Salomon J, Szepietowski JC, Proniewicz A. Psoriatic nails: a prospective clinical study. J CutanMedSurg. 2003;7(4):317-321.
Pasch MC. Nail psoriasis: a review of treatment options. Drugs. 2016;76:675-705.
Zaias N. Psoriasis of the nail. A clinical-pathologic study. Arch Dermatol. 1969;99(5):567-579.
de Jong EM, Seegers BA, Gulinck MK, Boezeman JB, van de Kerkhof PC. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology. 1996;193(4):300-303.
Ventura, et al. New insight into the pathogenesis of nail psoriasis and overview of treatment strategies Drug Design, Development and Therapy. 2017:11: 2527-2535.
Rich P, Scher RK. Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis. J AmAcadDermatol. 2003;49(2):206-212.
Cassell SE, Bieber JD, Rich P, et al. The modified nail psori-asis severity index: validation of an instrument to assess psoriatic nail in-volvement in patients with psoriatic arthritis. J Rheumatol. 2007;3:123-132.
Parrish CA, Sobera JO, Elewski BE. Modification of the nail psoriasis severity index. J AmAcadDermatol. 2005;53:745-751.
Jong EM, Menke HE, van de Praag MC, van De Kerkhof P. C. Dystrophic psoriatic fingernails treated with 1 % 5-fluorouracil in a nail penetra-tion-enhancing vehicle: a double-blind study. Dermatology. 1999;199:313-321.
Jones SM, Armas JB, Cohen MG, et al. Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol. 1994;33:834-843.
Baran R L. A nail psoriasis severity index. Br J Dermatol. 2004;150:568-577.
Karlijn MG, Klaassen MD, Peter CM, et al. Scoring nail psoriasis. J Am AcadDermatol. 2014;6:1061-1066.
Cannavo SP, Guarneri F, Vaccaro M, Borgia F, Guarneri B. Treatment of psoriatic nails witht opical cyclosporin: aprospective, randomized placebo-controlled study. Dermatology 2003;206:153-156.
Arora S, Debatraya P, Richa K, et al. Study of nail psoriasis and dermoscopic correlation with dermoscopic and modified dermoscopic nail psoriasis severity indexes (dNAPSI and dmNAPSI). DermatolPractConcept. 2022;12(1): e2022010. https://doi.org/10.5826/dpc.1201a10
Ortonne JP, Baran R, Corvest M, Schmitt C, Voisard JJ, Taieb C. Development and validation of Nail Psoriasis Quality of Life Scale (NPQ10). J EurAcadDermatolVenereol. 2010;24(1):22-27. https://doi.org/10.1111/j.1468-3083.2009.03344.x
Augustin M, Blome C, Costanzo A, Dauden E, Ferrandiz C, Girolomoni G, Gniadecki R, Iversen L, Menter A, Michaelis-Wittern K, Morita A, Nakagawa H, Reich K. Nail assessment in psoriasis and psoriatic arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes. Br J Dermatol. 2014;170:591-598. https://doi.org/10.1111/bjd.12664
Platonova AV, Zhukov AS, Khairutdinov VR, Samtsov AV. Psoriatic onychodystrophy: indices for assessing the severity of psoriatic onychodystrophy (part 2). Vestnik Dermatologii i Venerologii. 2019;95(1):9-14. https://doi.org/10.25208/0042-4609-2019-95-1-9-14
Piraccini BM, Iorizzo M, Antonucci A and Tosti A. Druginduced nail abnormalities. Expert Opinion on Drug Safety. 2004;3(1):57-65.
Pasch MC. Nail Psoriasis: A Review of Treatment Options. Drugs. 2016; 76:675-705. https://doi.org/10.1007/s40265-016-0564-5
Saulite I, Pilmane M, Kisis J. Expression of antimicrobial peptides in nail psoriasis and normal nails. ActaDermVenereol. 2017;97(5): 644-645.
McGonagle D, Benjamin M, Tan AL. The pathogenesis of psoriatic arthritis and associated nail disease: not autoimmune after all? CurrOpinRheumatol. 2009;21(4):340-347.
Gniadecki R. Next-generation antipsoriatic drugs: small molecules join. Br J Dermatol. 2015;173(6):1355-1356.
Iyer SS, Cheng G. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. CritRevImmunol. 2012;32(1):23-63.
Goldminz AM, Au SC, Kim N, Gottlieb AB, Lizzul PF. NF-κB: an essential transcription factor in psoriasis. J DermatolSci. 2013;69(2):89-94.
Crowley JJ, Weinberg JM, Wu JJ, Robertson AD, Van Voorhees AS; National Psoriasis Foundation. Treatment of nail psoriasis: best practice recommendations from the Medical Board of the National Psoriasis Foundation. JAMA Dermatol. 2015;151(1):87-94.
Saggini A, Chimenti S, Chiricozzi A. IL-6 as a druggable target in psoriasis: focus on pustular variants. J Immunol Res. 2014;2014:964069.
Manhart R, Rich P. Nail Psoriasis. ClinExpRheumatol. 2015;33:S7-S13.